Rituximab

Serum sickness: case report

In a retrospective observational study of 6 patients, one male patient [age not stated] was described, who developed serum sickness during treatment with rituximab for anti-MAG neuropathy [route not stated; duration of treatment to reaction onset not stated and outcome not stated]. The man, who had anti-MAG neuropathy, started receiving rituximab infusion 375 mg/m² weekly for consecutive 4 weeks. After receiving first infusion of rituximab, he developed serum sickness. However, remaining 3 infusions were subsequently given without any adverse effects.

Mazzeo A, et al. Rituximab usefulness as treatment of anti-mag associated neuropathy. Journal of the Peripheral Nervous System 26 (Suppl.): S24 abstr. 44, Nov 2021. Available from: URL: http://doi.org/10.1111/jpns.12472 [abstract]